SAN.PA : Summary for SANOFI - Yahoo Finance

U.S. Markets close in 2 hrs 26 mins

Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
75.08-0.02 (-0.03%)
At close: 11:35 AM EST
People also watch:
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close75.10
Open75.18
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range74.32 - 75.43
52 Week Range62.50 - 80.90
Volume4,148,690
Avg. Volume2,851,703
Market Cap95.1B
BetaN/A
PE Ratio (TTM)23.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters12 hours ago

    EU regulator accepts Sanofi/Regeneron's Dupixent product for review

    The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday. Dupixent is aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. If cleared by regulators, Dupixent would be the first approved systemic treatment for eczema, which in severe cases produces infection-prone rashes and a constant itch as bad as poison ivy.

  • PR Newswire13 hours ago

    Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

    TARRYTOWN, N.Y. and PARIS, Dec. 8, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) immune response, which is believed to be a major driver in the pathogenesis of the disease. The objective of the studies was to evaluate Dupixent as monotherapy (SOLO 1 and SOLO 2) and in concomitant administration with topical corticosteroids (CHRONOS) in adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies.

  • TheStreet.comyesterday

    Actelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP

    The chances of the French drug company muscling in on Johnson & Johnson's talks with Actelion are slim, based on Sanofi's cost of capital vs. return from a possible deal.